Mitochondria as a target for neurotoxins and neuroprotective agents
about
sameAs
Evaluation of Dimebon in cellular model of Huntington's diseaseTranslatability scoring in drug development: eight case studiesLatrepirdine for Alzheimer's diseaseDimebon for Alzheimer's diseaseNovel therapeutics for Alzheimer's disease: an updateDiscovery of a proneurogenic, neuroprotective chemicalLocal melatoninergic system as the protector of skin integrityCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseMitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's DiseasesMitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic interventionSerotonin-kynurenine hypothesis of depression: historical overview and recent developmentsTargeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunitiesImproved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetamUltrasensitive label-free photothermal imaging, spectral identification, and quantification of cytochrome c in mitochondria, live cells, and solutions.Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis.Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson diseaseAcute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivoThe metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptideMitochondrial Drugs for Alzheimer Disease.Current treatment and recent clinical research in Alzheimer's diseaseThe rise and fall of Dimebon.Drug development for Alzheimer's disease: where are we now and where are we headed?Development of proneurogenic, neuroprotective small molecules.Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's diseaseMitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.Frontiers in Alzheimer's disease therapeutics.Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies.The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeysDrug development for Alzheimer's disease: recent progressDimebon slows progression of proteinopathy in γ-synuclein transgenic mice.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.N-acetylserotonin and aging-associated cognitive impairment and depression.NMDA receptors in clinical neurology: excitatory times ahead.Huntington's disease: progress and potential in the field.Potential Role of Caffeine in the Treatment of Parkinson's Disease.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability.The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments.Mitochondrial structural and functional dynamics in Huntington's disease.
P2860
Q21202838-4B7BFF84-3F4B-4B60-842C-8B582C14ED66Q22241760-D05C00D7-5E21-48CF-BD5A-86D24EF989C7Q24186444-8BA24077-6644-4C17-8727-F9279F3298D9Q24234998-15DA2EBA-E48B-4F33-BF1E-831BFB69CE00Q24620383-BDBFF08A-2D1F-45E9-95DF-1246DB7B6584Q24620801-B4DD4076-E997-453E-8106-82BEFDA11E01Q26828985-86EBFA69-48CF-4837-B8DC-CF32E532D65DQ26829899-6CAD6512-B0BB-4010-9A45-BA71511FAD9FQ26859141-C3AD5364-E1FB-4104-B4E0-A05AC5C17668Q26865358-7D0D5BF0-647F-4738-840A-2963C0D0101FQ27012779-279587F1-3F74-4003-8253-E5E56E067937Q27338799-72C3FD97-7FC2-4F82-A4C5-85E1E80BF459Q27500402-14CA69B9-4B2F-4DD5-992C-6D7938C07B1FQ28384303-0A13CB2B-5B20-40BB-B585-EA956BC81BBCQ30525846-27BF2DB2-F871-437B-94AF-75727FB142A7Q30525849-4F463A45-B205-4CE5-9F78-3BE8AFF9908EQ33592247-39A60A78-EE50-44EB-9982-88C1F530139AQ33870388-7A0945F9-6C15-44EB-B919-DDC2568997C5Q34016406-6B68133D-7348-452A-B676-DF3CF40559A0Q34067487-E2F87749-1F1A-419F-A62E-2BE37D40A6F6Q34146766-43D1D0E3-FA3D-448D-8C7E-45FFC9FE9580Q34166256-77AEA2E8-D9E2-4F5C-8942-B5ED3EB10C40Q34551056-90A5F0CF-A636-4C8E-9A98-DBE7D814A7B8Q34557710-038AF643-BB1F-44D1-A6EA-7DF0F7B370C3Q34994270-08DB092F-DB3B-4847-A79E-40FF644E6FE2Q35086876-B4F11338-1925-4499-80F6-31230876862BQ35140660-3F04D1DC-3A06-43EE-A3F9-6363FB347F57Q35376045-AFBDACA3-2257-4742-8C19-C093750FC15FQ35545974-DDB30D27-8701-4DEB-B9ED-90F42FE4506DQ35957568-BBD59B7B-2AF9-4C9F-8938-BEDCD6482B37Q35958359-8A1B4187-80A0-4FD4-84D7-0A951DE4A459Q36304050-1B02F671-CBD3-4ED3-BB4A-3B44D7BEDD9BQ36409066-650A0A4A-B009-4AAC-9C8D-72940E091922Q36660216-CE76B03D-5742-422A-B2A3-8A6F8A2FE72EQ37016096-C06DD6AC-7BCA-4126-8E27-2FC3754D7F22Q37129378-80EC056B-7061-4EC3-BCA7-549F85768467Q37198579-980ADDBC-2176-42B8-A8F8-697694714045Q37281161-C640E164-7385-4E1F-8B30-81468E2308B5Q37334202-CD9E2F9F-9B60-4EF1-8944-CAC431B8BA17Q37356257-2CA14E75-0E92-42DA-9D40-DEB86F8CF3C9
P2860
Mitochondria as a target for neurotoxins and neuroprotective agents
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mitochondria as a target for neurotoxins and neuroprotective agents
@ast
Mitochondria as a target for neurotoxins and neuroprotective agents
@en
Mitochondria as a target for neurotoxins and neuroprotective agents
@nl
type
label
Mitochondria as a target for neurotoxins and neuroprotective agents
@ast
Mitochondria as a target for neurotoxins and neuroprotective agents
@en
Mitochondria as a target for neurotoxins and neuroprotective agents
@nl
altLabel
Mitochondria as a Target for Neurotoxins and Neuroprotective Agents
@en
prefLabel
Mitochondria as a target for neurotoxins and neuroprotective agents
@ast
Mitochondria as a target for neurotoxins and neuroprotective agents
@en
Mitochondria as a target for neurotoxins and neuroprotective agents
@nl
P2093
P3181
P1476
Mitochondria as a Target for Neurotoxins and Neuroprotective Agents
@en
Mitochondria as a target for neurotoxins and neuroprotective agents
@en
P2093
ELENA G. KIREEVA
ELENA P. SHEVTSOVA
Elena G Kireeva
Elena P Shevtsova
GREGORY F. OXENKRUG
Gregory F Oxenkrug
SERGEY O. BACHURIN
SERGEY O. SABLIN
Sergey O Bachurin
Sergey O Sablin
P304
334-44; discussion 345-9
P3181
P356
10.1111/J.1749-6632.2003.TB07541.X
P407
P577
2003-05-01T00:00:00Z